secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0000950170-25-062742
Event type: other_material
Sentiment:  negative
Materiality: 0.95
Item codes: 5.03, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics stockholders approve 20x authorized share increase to 2B; massive dilution authorized
--------------------------------------------------------------------------------

- Authorized common shares increased from 100M to 2B; reverse split authorized at ratio between 1:25 and 1:250.
- Stockholders approved issuance of up to 1.26B shares upon exercise of Series B Warrants with zero exercise price.
- Warrant exercise price reset to floor of $0.132; Series A/B could total ~1.68B shares if fully exercised.
- All proposals passed with >88% votes for; quorum of 8.2M shares out of 11.8M outstanding.
- Item 8.01 confirms massive potential equity dilution from prior private placement warrants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017025062742/0000950170-25-062742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017025062742/pstv-20250502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-062742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer